Background: Epicardial placement of the left ventricular (LV) lead via a video-assisted thoracoscopic (VAT) approach is an alternative to the standard transvenous technique.
area, pacing measurements are taken and a spiral screw electrode is anchored at the final pacing site. The electrode is then tunneled to the pectoral pocket and connected to the device.
Results: 105 patients were referred to our center for epicardial LV lead implantation.
After pre-operative assessment, 5 patients were excluded because of concomitant conditions precluding surgery. The remaining 100 underwent the procedure. LV lead implantation was successful in all patients (median pacing threshold 0.8 ± 0.5 V, no phrenic nerve stimulation) and cardiac resynchronization therapy was established in all but one patient. The median procedure time was 75 min. During a median followup of 24 months, there were no differences in terms of death, cardiovascular hospitalizations or device-related complications vs the group of 100 patients who had undergone transvenous implantation. Patients of both groups displayed similar improvements in terms of ventricular reverse remodeling and functional status.
Conclusions: Our VAT approach proved safe and effective, and is a viable alternative in the case of failed transvenous LV implantation.
| INTRODUCTION
Epicardial placement of left ventricular (LV) lead has been proposed as an alternative approach in the case of failure of the transvenous approach during cardiac resynchronization therapy (CRT) device implantation. In our center we developed a minimally invasive videoassisted thoracoscopic (VAT) technique. We reviewed our experience in order to evaluate the safety and efficacy of this technique. We also assessed long-term safety and efficacy by comparing the outcome of the study group with that of a control group of patients who underwent standard transvenous LV lead implantation.
| METHODS

| Patient selection
The study was approved by the Institutional Review Board and all subjects provided written consent. Patients underwent baseline evaluation, which included demographics and medical history, clinical examination, 12-lead electrocardiogram, and echocardiogram. Patients were also evaluated by means of a CT scan to rule out any thoraco-pulmonary disease, spirometry with diffusing capacity of the lung for carbon monoxide, and anesthesiology evaluation. In all patients, previous LV lead implantation had been unsuccessful, owing to unsuitable coronary or subclavian venous anatomy, LV lead dislodgement or failure, phrenic nerve stimulation not correctable by reprogramming, or lead extraction because of infection.
| Surgical technique and approach
The technique has been previously described. 1 In summary, after a general anesthetic had been administered, a double-lumen endotracheal tube was inserted. With the patient in a right lateral decubitus position (90 ) and on single-lung ventilation, three ports (2 × 5 mm; 
| Patient management
Patients were extubated in the operating room or in the Intensive Care Unit. The chest tube was removed 12 to 24 hours after surgery.
No redo surgery was necessary. After discharge, clinic visits were scheduled every 6 months.
| Control group
A group of 100 consecutive patients who underwent successful transvenous CRT implantation in our center was used as a control group.
| Endpoints
Primary end-points were: time to death due to any cause and time to the combination of death and cardiovascular hospitalization. Additional endpoints were: device-related complications, LV ejection fraction and volume change, NYHA class, and ventricular pacing parameters. The remaining 100 patients underwent the surgical procedure.
| Statistical analysis
| Study population
An additional group of 100 consecutive patients who had undergone successful transvenous LV lead implantation in the period between 2012 and 2015 was analyzed in order to compare long-term outcomes and event rates. Table 1 shows the clinical characteristics of the two groups.
In the thoracoscopic group, LV lead implantation was successful in all patients and CRT was successfully established in all but one patient at the end of the procedure. The median pacing threshold was 0.8 V at 0.5 ms (IQR 0.6-1.2) and no phrenic nerve stimulation was reported at the final electrode position. Fixation in a basal LV segment was achieved in 90 (90%) patients. The median total procedure time was 75 min (IQR 55-95) and the time to epicardial lead fixation was 30 min (IQR 15-40). The procedure time was significantly longer in the presence of pleural adherence (127 ± 47 min vs 71 ± 25 min, with vs without, P < .001) or pericardial adherence (115 ± 48 min vs 74 ± 30 min, with vs without, P = .004). No complications were reported, except for two cases of transitory peri-electrode bleeding and three cases of ventricular fibrillation induced during the procedure. No sequelae were reported for all these events. During the post-operative hospital stay, 12 complications occurred in nine patients: five cases of worsening heart failure, one followed by death, four pocket or chest-wall hematomas (only one requiring intervention), one episode of ventricular tachycardia correctly interrupted by the ICD, one episode of atrial fibrillation, and one dislocation of the right ventricular defibrillation lead, causing inappropriate shocks. The median hospital stay after the procedure was 5 days (IQR 3-7).
In the transvenous group, the median LV lead pacing threshold was 1.1 V at 0.5 ms. The final position of the LV lead was lateralanterolateral. Table 2 compares procedural data of the two groups.
| Follow-up
In the thoracoscopic group, 21 deaths occurred during a median follow-up period of 24 months (IQR, 13-39); in the transvenous group, 27 deaths occurred during a median follow-up of 32 months (IQR, . The rates of death due to any cause were comparable between the groups (Figure 1 ; log-rank test, P = .193). The rates of death due to any cause and cardiovascular hospitalization were also comparable between the groups (Figure 1 ; log-rank test, P = .949).
Moreover, the risk of device-related complications was similar between the groups. Figure 2 shows the survival from device-related complications in both groups (log-rank test, P = .783). In the thoracoscopic group, we recorded five infections (requiring system revision only in one patient), four pocket hematomas (not requiring system revision), one right ventricular lead dislodgement, one system failure, and one replacement of the LV lead. In the transvenous group, six patients had LV lead dislodgement, three had pocket erosion, two had right ventricular lead dislodgement, one had right atrial lead dislodgement, and one system failure.
In both groups, significant reverse remodeling of the LV was observed in terms of increased LV ejection fraction and reduced LV volumes ( Table 3 ). Patients of both groups similarly improved in their functional status, as evidenced by a reduction of patients in NYHA class III-IV at 1-year follow-up. The pacing parameters remained satisfactory in both groups (Table 3 ).
| DISCUSSION
In clinical practice, the first-line approach to LV lead implantation dur- 4 Many experiences have been published on LV pacing via trans-septal approach,3, 5-14 but no randomized studies have compared its efficacy with that of the epicardial approach.
There are several open-chest techniques to implanting the LV 16, 17 in addition to several other non-randomized studies. [16] [17] [18] [19] [20] [21] [22] [23] [24] The VAT technique causes less postoperative pain and requires smaller incisions. The lateral approach enables the target area of the LV (basal postero-lateral) to be reached more easily than in the supine position previously suggested. 19 Previous studies have been published on the VAT technique. [19] [20] [21] 24, [28] [29] [30] [31] [32] [33] [34] [35] [36] We showed that the VAT approach is safe and effective. We included both patients who had undergone unsuccessful de novo transvenous LV lead implantation and patients who had 
| Study limitations
The main limitation is its lack of randomization. The study group con- 
